Overview
Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)
Status:
Completed
Completed
Trial end date:
2011-03-01
2011-03-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this post-marketing surveillance is to detect adverse drug reactions (particularly clinically significant adverse drug reactions) occurring in clinical settings, to examine factors likely to affect the safety and efficacy in the Japanese asthma patients treated with fluticasone propionate and salmeterol xinafoate.Details
Lead Sponsor:
GlaxoSmithKlineTreatments:
Fluticasone
Fluticasone Propionate, Salmeterol Xinafoate Drug Combination
Fluticasone-Salmeterol Drug Combination
Salmeterol Xinafoate
Criteria
Inclusion Criteria:- Must use fluticasone and salmeterol for the first time
Exclusion Criteria:
- Patients with hypersensitivity to salmeterol and fluticasone
- Patients with infection which salmeterol and fluticasone is not effective
- Patients with deep mycosis